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Abstract
The international community has committed to ending the tuberculosis (TB)
epidemic by 2030. This will require multi-sectoral action with a focus on
accelerating socio-economic development, developing and implementing new
tools, and expanding health insurance coverage. Within this broad framework,
National TB Programmes (NTPs) are accountable for delivering diagnostic,
treatment, and preventive services. There are large gaps in the delivery of
these services, and the aim of this article is to review the crucial activities and
interventions that NTPs must implement in order to meet global targets and
milestones that will end the TB epidemic. The key deliverables are the
following: turn End TB targets and milestones into national measurable
indicators to make it easier to track progress; optimize the prompt and accurate
diagnosis of all types of TB; provide rapid, complete, and effective treatment to
all those diagnosed with TB; implement and monitor effective infection control
practices; diagnose and treat drug-resistant TB, associated HIV infection, and
diabetes mellitus; design and implement active case finding strategies for
high-risk groups and link them to the treatment of latent TB infection; engage
with the private-for-profit sector; and empower the Central Unit of the NTP
particularly in relation to data-driven supportive supervision, operational
research, and sustained financing. The glaring gaps in the delivery of TB
services must be remedied, and some of these gaps will require new
paradigms and ways of working which include patient-centered and
higher-quality services. There must also be fast-track ways of incorporating
new diagnostic, treatment, and prevention tools into program activities so as to
rapidly reduce TB incidence and mortality and meet the goal of ending TB by
2030.
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Introduction
If you always do what you always did, you will always get what 
you always got.
Albert Einstein
The Sustainable Development Goals (SDGs), adopted by 
United Nations (UN) Member States in September 2015, 
and the World Health Organization (WHO) End TB Strat-
egy, endorsed by the WHO’s 194 Member States in 2014, have 
a common goal with respect to tuberculosis (TB): to end the 
global TB epidemic. Targets for meeting this goal include a 90% 
reduction in TB deaths and an 80% reduction in TB inci-
dence by 2030 compared with 2015: these targets also need to 
be achieved with no TB-affected families facing catastrophic 
costs1,2. Milestones have been set to help monitor progress along 
the way (Table 1).
Since the WHO took the extraordinary step in 1993 of declaring 
TB a “global emergency”, huge steps have been taken to control 
this ancient disease, once coined “the captain of all these men of 
death”3. The “DOTS” strategy launched by the WHO in 1995, 
which evolved into the “Stop TB” Strategy a decade later and 
then the “End TB” Strategy, has provided the successive frame-
works and targets for international and national control efforts. 
In 2000, the Millennium Development Goals (the predecessor 
to the SDGs) included a TB-specific target (6c) “to halt and 
reverse TB incidence” by 2015, and this was augmented by 
two Stop TB Partnership targets to halve TB prevalence and 
mortality by 2015 compared with levels in 1990. By 2015, TB 
incidence was halted and reversed, and TB-related mortality 
(deaths per 100,000 population per year) was decreased by 
47% overall between 1990 and 20144. TB treatment averted an 
estimated 49 million deaths globally between 2000 and 20154.
Despite this laudable progress, the disease remains an enormous 
global public health threat, especially for low- and middle-income 
countries. In 2016, an estimated 10.4 million new people devel-
oped TB and 1.7 million died, making TB the ninth leading cause 
of death worldwide and the leading cause from a single infec-
tious agent, ranking above HIV/AIDS5. Critical problems remain 
at large. TB control depends on preventing latent TB infection 
from becoming established or developing into active disease 
and on diagnosing and treating active disease as soon as it has 
developed. TB preventive treatment is expanding, but most 
of those eligible for this intervention are not accessing it. In 
2016, only 6.3 million new patients with TB were reported, 
meaning that 4.1 million (40% of the estimated disease burden) 
either were not diagnosed or were diagnosed but not notified to 
national programs5. Drug-resistant TB grows inexorably. In 2016, 
there were an estimated 600,000 new patients with resistance to 
rifampicin (RR-TB), of which 490,000 had resistance to both 
rifampicin and isoniazid, the two most-effective first-line 
drugs (multidrug-resistant TB, or MDR-TB). Only 22% of 
patients with MDR-TB were started on treatment, and of these 
only 54% were successfully treated. In 2016, HIV-associated 
TB accounted for 1.03 million patients and was responsible for 
374,000 deaths5.
Ending the TB epidemic will require multi-sectoral action with 
a focus on accelerating socio-economic development, develop-
ing a new TB vaccine, producing novel diagnostics and medi-
cines for treatment, and expanding health insurance coverage6. 
The years 2017 and 2018 were and are respectively landmarks 
for global efforts to end TB in the era of the SDGs. In Moscow 
in November 2017, the WHO hosted the first global Ministerial 
Conference on TB and the aim was to accelerate the implemen-
tation of the WHO End TB Strategy5. September 2018 will 
see the first UN General Assembly high-level meeting on TB at 
which a multi-sectoral approach and accountability framework 
will be agreed upon and endorsed by heads of state.
Within this broad framework, National TB Programmes (NTPs) 
are responsible and accountable for delivering high-quality 
and effective diagnostic, treatment, and preventive services 
and ultimately interrupting the transmission of Mycobacterium 
tuberculosis (MTB) from infected to non-infected persons7. To 
this end, the Stop TB Partnership, inspired by the Joint United 
Nations Programme on HIV/AIDS (UNAIDS) 90-90-90 treatment 
targets for HIV care and treatment8, in 2015 launched 90-(90)-
90 TB diagnostic and treatment targets as part of the Global 
Plan to accelerate the ending of the TB epidemic (Table 2)9. 
The aim of this article is to review the crucial activities and 
interventions that NTPs need to implement in order to meet 
the 90-(90)-90 TB targets and end the TB epidemic.
Turn End TB milestones and targets into measurable 
numbers
NTPs must work with the WHO to develop, at the national level, 
absolute numbers for milestones and targets on estimated TB 
Table 1. Global milestones and targets for ending tuberculosis by 2030.
Indicators Milestones Targets
2020 2025 SDGs 
2030
End TB 
2035
Percentage reduction in the absolute number of TB 
deaths (compared with 2015 baseline)
35% 75% 90% 95%
Percentage reduction in the TB incidence rate 
(compared with 2015 baseline)
20% 50% 80% 90%
Percentage of TB-affected households experiencing 
catastrophic costs due to TB (level in 2015 unknown)
0% 0% 0% 0%
SDG, Sustainable Development Goal; TB, tuberculosis. Adapted from reference 2.
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incidence and mortality for 2020, 2025, and 2030 so that these 
become easily understandable and visible indicators against 
which genuine progress can be measured. In the next eight 
years, for example, the annual decline in TB incidence has to 
accelerate from the current 1.5% per year to 5% per year 
by 2020 and to 10% per year by 20255. The proportion of 
people who die from TB likewise needs to decrease to 10% by 
2020 and to 6.5% by 2025. Translation of global percentage 
reductions to country target numbers allows NTPs to have bench-
marks and to determine in detail how their states, provinces, 
regions, and districts are performing. Countries that are lagging 
behind should be given additional support to hasten progress, while 
those that are doing well need encouragement and praise. This 
approach is not new and was adopted by Malawi in 2004 when 
it successfully implemented the WHO’s “3 by 5” initiative 
for scaling up antiretroviral therapy (ART) country-wide10.
Optimize systems for prompt and accurate diagnosis 
of tuberculosis
There are two prongs to the diagnosis of TB: accurate identifica-
tion of the disease and ascertainment of the drug-susceptibility 
status of MTB. Microbiological examination of sputum smears 
for acid-fast bacilli, with or without chest radiography, has long 
been the mainstay of TB diagnosis in resource-poor countries. 
However, because this method is diagnostically insensitive and 
cannot be used to assess drug-susceptibility status, molecular 
technology is rapidly taking over. The WHO-preferred test 
is the Xpert MTB/RIF assay (Cepheid Inc., Sunnyvale, CA, 
USA). This is a highly sensitive, fully-automated, and com-
mercially available nucleic acid amplification test for use with 
sputum and other bodily specimens11. The assay requires minimal 
expertise and has a short sample processing time of 2 hours to 
confirm the presence of MTB and to detect rifampicin resistance.
Xpert MTB/RIF was initially used for high-risk groups, but in 
2013 the WHO recommended that the assay be considered the 
initial diagnostic test for all people requiring investigation for 
TB12. Between 2010 and 2016, nearly 6,700 Xpert instruments 
were procured by NTPs in 130 of 145 countries eligible for 
concessional pricing, and, in 2016 alone, this included 6.9 
million test cartridges5. These impressive statistics, however, 
belie major challenges with the use of Xpert MTB/RIF, such as 
the need for stable and regular electricity, adequate mainte-
nance, and uninterrupted cartridge supplies13. In many countries, 
installed instruments are underutilized; the island of Kiribati, 
which has a significant TB burden, is an illustration of this 
point14.
NTPs should consider four practical steps to improve systems 
for TB diagnosis. First, with many programs in resource-
poor areas still in the process of scaling up Xpert technology, 
a mixture of smear microscopy and Xpert MTB/RIF is used. 
NTPs need to work out how and where these two diagnostic 
systems are deployed and the most practical and effective 
algorithms for their use.
Second, NTPs need to have accurate and timely records of 
numbers presenting with presumptive TB, numbers who submit 
sputum or other bodily specimens for laboratory investiga-
tion, and numbers diagnosed with bacteriologically confirmed 
TB. This cascade should be routinely monitored and is a fertile 
area for operational research. A recent review in primary care 
clinics in South Africa showed that 20% of patients with classic 
TB symptoms were never screened by health-care staff and 
that 80% of patients who were screened and identified with TB 
symptoms failed to submit the necessary sputum specimens15. 
These system-related deficiencies suggest that much more 
can be done within the health-care setting to identify patients 
with presumptive TB and ensure that they are appropriately 
investigated.
Third, depending on the number of modules per Xpert MTB/RIF 
instrument (the usual instrument has four modules), it is sim-
ple to calculate the number of expected assays that should be 
performed per instrument per month and then to monitor the 
number of assays actually performed against this target. Such 
information is critical for evaluating the proper deployment and 
effective use of these instruments.
Finally, NTPs must keep abreast of new developments in 
molecular technology. Xpert MTB/RIF has its limitations, which 
include suboptimal sensitivity and a high rate of false positivity 
in low-prevalence settings. To overcome this, the assay was 
re-engineered to increase diagnostic sensitivity and improve 
specificity in the detection of rifampicin resistance. The result-
ing Xpert MTB/RIF Ultra assay is run on the same instrument 
as Xpert and requires only a software upgrade16. In 2017, based 
on a technical expert consultation, the WHO recommended 
the use of Xpert MTB/RIF Ultra in all settings as a replace-
ment for Xpert MTB/RIF17. However, such replacement comes 
with advantages and disadvantages. A recent multi-center study 
showed increased sensitivity of Xpert MTB/RIF Ultra, especially 
in patients with paucibacillary disease and HIV co-infection, 
but this was at the expense of decreased specificity, especially in 
those with a history of TB18. Additional work and research are 
needed to provide solutions to these problems.
Table 2. 90-(90)-90 People-centered global targets for tuberculosis.
•   Reach and treat at least 90% of all people with TBa 
•   As a part of this approach, reach and treat at least (90%) of the key populationsb 
•   Achieve at least 90% treatment success for all people diagnosed with TBc
TB, tuberculosis. aIncludes people with both drug-susceptible and drug-resistant TB as well as 
people who require preventive therapy (for example, people living with HIV and those in contact 
with patients with TB). bIncludes vulnerable, underserved, and at-risk populations which vary 
depending on country context. cIncludes achieving 90% treatment success among people 
diagnosed with both drug-susceptible and drug-resistant TB as well as people who require TB 
preventive therapy. Adapted from reference 9.
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Xpert Omni (a portable, battery-operated, single-cartridge, point-
of-care device) is currently undergoing field evaluation, and 
launch is expected in 201919. If costs permit (and worryingly these 
do appear to be rising), this might allow further decentralization 
of molecular diagnostic technology and improved patient access.
Provide rapid, complete, and effective treatment to all 
those diagnosed with tuberculosis
All patients diagnosed with TB should receive prompt, complete, 
and effective treatment with appropriate nutritional and psycho- 
social support. In practice, this does not happen. In Africa, Asia, 
and the Western Pacific, between 4% and 38% of patients with 
laboratory-detected sputum smear-positive or culture-positive 
TB fail to start treatment20. This outcome, known as pre-treatment 
loss to follow-up, appears to be no better with the use of Xpert 
MTB/RIF, and pre-treatment loss to follow-up varies from 
21% in Cameroon to 30% in Myanmar and to 45% in South 
Africa21–23. For patients who do get treated, the turn-around 
time between confirmed diagnosis and treatment initiation can 
also be lengthy, compromising individual care and increasing 
the risk of MTB transmission within families and communities.
This disconnection between laboratories, treatment facilities, 
and patients has to change. District TB officers must be held 
accountable for linking diagnosed patients to treatment. One 
simple method is to regularly identify all bacteriologically 
confirmed TB patients in the laboratory register and check that 
they have been entered into the patient TB treatment register. In 
the 1990s, the Malawi NTP adopted this system and set a national 
performance target that at least 90% of diagnosed patients should 
start standardized treatment24. Time between diagnosis and 
start of treatment should also be monitored, and targets should 
be set for what constitutes an unacceptable time interval (for 
example, more than 7 days). Serious consideration should 
also be paid to report treatment outcomes on all diagnosed TB 
patients and not just on those registered for treatment, as is 
the current procedure. A study in Ghana showed that although 
treatment success of registered patients with TB was high at 
87%, this reduced to 54% when diagnosed patients served as 
the cohort denominator25. Unless this change is made, NTPs 
will be unable under routine program conditions to measure 
the third pillar of the Global TB Plan, namely whether 90% of 
their diagnosed patients have successfully completed treatment9.
WHO guidelines (2009 and 2017) specify that new patients 
with drug-susceptible TB be treated with a standardized regi-
men of isoniazid and rifampicin for 6 months, supplemented 
with pyrazinamide and ethambutol for the first 2 months26,27. 
Standardization of medication dosages by body weight, use of 
fixed-dose combinations and patient treatment kits, and insistence 
that drugs be given under direct observation (directly observed 
therapy, or DOT) have facilitated treatment administration and 
improved patient adherence to medication. Community- or 
home-based DOT is recommended, and DOT by trained 
community volunteers/workers or formal health-care workers 
is preferred over DOT that is administered by family members. 
This system, which is followed by NTPs worldwide, has con-
tributed to high treatment success rates of registered patients, 
and the latest outcome data show a global treatment success of 
83%5.
However, there is room for improvement. Treatment outcome 
definitions were revised by the WHO in 2013 (Table 3)28. “Not 
evaluated” is an outcome given to a patient for whom no treat-
ment outcome is assigned, and rates of “not evaluated” can be 
high. In the 2013 WHO African region cohort, 9% of patients 
with TB were classified as “not evaluated”, impacting nega-
tively on the overall treatment success rate29. “Not evaluated” 
includes patients who are transferred out to another treatment 
unit and whose treatment outcome is unknown. Transfers 
during anti-TB treatment are common and often are associ-
ated with no treatment outcome in the TB treatment register30,31. 
District TB officers, using mobile phones and other modern 
communication methods, can significantly reduce this correct-
able adverse outcome and ensure that all of their transferred-out 
patients have a documented outcome in the register.
Implement and monitor effective infection control 
practices
Infection control is the basis for preventing exposure to MTB 
among non-infected individuals in health facilities and other 
congregate settings. Health facility exposure accounts for a 
Table 3. Definitions of treatment outcomes for patients with drug-susceptible tuberculosis.
Outcome Definition
Cure A bacteriologically confirmed TB patient at the beginning of treatment who was found to be smear- or culture-
negative in the last month of treatment and on at least one previous occasion
Treatment completed A TB patient who completed treatment without evidence of failure but with no record to show that sputum smear 
or culture results in the last month of treatment and on at least one previous occasion were negative, either 
because the tests were not done or because the results are unavailable
Treatment failure A TB patient whose sputum smear or culture is positive at month 5 or later during treatment
Died A TB patient who dies for any reason before starting or during the course of treatment
Lost to follow-up A TB patient who did not start treatment or whose treatment was interrupted for two consecutive months or more
Not evaluated A TB patient for whom no treatment outcome is assigned; this includes patients “transferred-out” to another 
treatment unit as well as patients for whom the treatment outcome is unknown to the reporting unit
Treatment success The sum of cured and treatment completed
TB, tuberculosis. Adapted from reference 28.
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significant proportion of total TB infection risk for patients who 
repeatedly attend health facilities for chronic care in high-TB 
burden settings32. Health-care staff are similarly at high risk33. In 
the high-HIV prevalence areas of Southern Africa, devastating 
and lethal outbreaks of drug-resistant TB have occurred in the 
open and crowded hospital wards and out-patient facilities34,35.
NTPs must pay attention to the WHO TB infection control 
guidelines which focus on early identification, isolation, and 
treatment of those with presumptive TB, infrastructure modifi-
cations (such as enlarged windows, open skylights, and open-air 
waiting rooms) to ensure appropriate natural ventilation and air 
flow, use of ultraviolet germicidal irradiation fixtures (if applicable 
and affordable), better organization to avoid patient congestion, 
and provision of personal protective measures for health workers 
(Table 4)36. For drug-resistant TB, the introduction of the FAST 
strategy (find cases actively, separate safely, and treat effectively) 
has been associated with a significant reduction of hospital-
based acquisition of MDR-TB in the Russian Federation37, 
and this approach should be encouraged in other countries. 
An important monitoring indicator for effective implemen-
tation within health facilities is the number and proportion 
of health-care workers who develop TB each year, and this 
should be routinely reported by NTPs.
Diagnose and promptly treat drug-resistant 
tuberculosis
Both RR/MDR-TB require prolonged treatment (traditionally 
up to 24 months) with second-line anti-TB drugs, which are less 
effective and more costly and are associated with more adverse 
events compared with first-line drugs (Table 5)38,39. About 10% 
of patients with MDR-TB have additional resistance to fluo-
roquinolones or second-line injectable agents (termed extensively 
drug-resistant TB, or XDR-TB) or both. XDR-TB is best 
treated with regimens that include bedaquiline and linezolid, but 
even so about one-third of treated XDR-TB patients have 
unfavorable treatment outcomes of death, failure, and loss to 
follow-up40. These adverse treatment outcomes contribute to 
a growing and dangerous problem of patients with program-
matically incurable TB. Globally, in 2016, 4% of new cases and 
19% of previously treated TB cases had MDR-TB, and nearly 
half of the world’s cases are in China, India, and the Russian 
Federation5. Some countries in Eastern Europe and Central Asia 
have alarming levels of disease; a national prevalence survey 
in the Ukraine found the proportions of MDR-TB among new 
and previously treated cases to be 24% and 58%, respectively41.
Countries with known high levels of MDR-TB should test all 
new and previously treated cases of TB for rifampicin resist-
ance by using Xpert MTB/RIF. Those with lower drug-resistance 
burdens must examine their resources and decide, for exam-
ple, whether to prioritize all previously treated TB cases for 
Xpert MTB/RIF and work out when to use Xpert MTB/RIF on 
new cases that are diagnosed through smear microscopy.
Many countries still like to confirm their RR-TB Xpert results 
with conventional culture and drug sensitivity testing (CDST) 
in national reference laboratories, and this requires the transpor-
tation of sputum specimens from peripheral health facilities. 
Wherever this system has been assessed, it does not function42–45, 
and transportation is the major bottleneck. Other obstacles 
include the formation of committees to approve MDR-TB 
treatment and a battery of hematological and biochemical tests 
which are considered necessary in all settings before treatment 
can be started. Although these procedures may be necessary 
when new drugs such as bedaquiline and delamanid are intro-
duced in programmatic settings, they can contribute to diagnosed 
patients either failing to start treatment or experiencing significant 
Table 4. Infection control guidelines for reducing transmission of Mycobacterium tuberculosis in health 
facilities.
Facility-level measures
•   Redesign the use of available spaces, renovate existing facilities, or construct new facilities
•   Conduct on-site surveillance of TB in health workers
•   Discuss TB transmission with health workers, patients, and visitors
•   Monitor the package of TB infection control measures
Administrative measures
•    Promptly identify people with TB symptoms, separate potentially infectious and confirmed infectious patients 
from others, institute cough etiquette and respiratory hygiene, and minimize time spent in health-care facilities
•    Provide prevention and care interventions for health workers, including HIV prevention, antiretroviral therapy, 
and isoniazid preventive therapy for HIV-positive health workers
Environmental protection
•    Ensure good natural ventilation (open windows and doors, enlarged or additional windows, and open skylights 
for cross-ventilation)
•    Use ultraviolet germicidal irradiation fixtures (if applicable and affordable, especially in cold climates when 
windows and skylights remain shut)
Personal protection
•   Use particulate respirators especially for managing drug-resistant TB
TB, tuberculosis. Adapted from reference 36.
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delays. NTPs must decide what to do: whether to streamline 
the preparatory phase for starting MDR-TB treatment and 
whether to maintain but fix their national reference labora-
tory CDST systems or alternatively dispense with CDST and 
focus on scaling up and decentralizing their diagnostic molecular 
technology.
This is not an easy decision. The WHO has recently recommended 
a new short-course regimen of 9 to 12 months for MDR-TB 
provided that patients have not been treated with second-line 
drugs and/or have had resistance to fluoroquinolones and 
second-line injectable agents excluded46. This regimen in eli-
gible patients is well tolerated and, according to observational 
studies, has excellent treatment success rates both in Asia and in 
Africa47,48. Definitive and published results from the STREAM 1 
randomized controlled trial comparing the 9-month regimen with 
a 24-month regimen are awaited.
Currently, conventional CDST and molecular line probe assays 
(LPAs) performed in laboratories are the only ways of obtaining 
information on second-line drug resistance. LPAs are more 
rapid than conventional phenotypic drug sensitivity testing 
(DST) methods, allowing a rapid diagnosis of either MDR-TB 
or XDR-TB within 3 days either from sputum submission 
or after obtaining a pure culture of MTB. LPAs are therefore 
recommended by the WHO as the initial laboratory test instead 
of phenotypic DST for diagnosing MDR-TB or XDR-TB49,50. 
Good functioning and well-resourced laboratories plus well-
trained, skilled laboratory technicians are necessary for LPAs to 
perform well, and thus these assays are generally used only in 
national reference laboratories.
However, a new automated, cartridge-based assay has been 
developed that accurately detects MTB mutations associated with 
resistance to isoniazid, fluoroquinolones, and aminoglycosides, 
and this holds promise as a rapid point-of-care test to guide 
therapeutic decisions for patients with drug-resistant TB51. 
This will also facilitate the identification of isoniazid mono-
resistance, which may be found in 10% or more of patients and 
which currently needs conventional CDST or laboratory-based 
LPA for diagnosis. Isoniazid mono-resistance may be associated 
with worse treatment outcomes52, and the WHO recommends that 
high levels of isoniazid mono-resistance warrant a change of regi-
men to rifampicin, ethambutol, pyrazinamide, and levofloxacin53.
Diagnose and treat HIV infection and diabetes 
mellitus
HIV infection
The HIV epidemic has hampered TB control efforts globally, 
especially in the high-HIV prevalence areas of Southern and 
Eastern Africa. Case fatality rates are several times higher in 
patients with HIV-associated TB compared with those who 
have just TB54. ART, however, results in excellent immuno-
logical and virological responses and a reduction in mortality 
risk of 64% to 95%55. Cotrimoxazole preventive therapy (CPT) 
augments this response and, when combined with ART, further 
reduces mortality and morbidity56.
HIV testing is the gateway to such integrated care, but in 2016 
only 57% of notified TB cases globally had a documented 
HIV test; the figure was highest in the Africa region at 82%5. 
The WHO recommends ART for all HIV-positive TB patients 
within the first 8 weeks of starting anti-TB treatment but, 
Table 5. Second-line drugs recommended for the treatment 
of multidrug-resistant tuberculosis.
Drug class Name of drug
Fluoroquinolones Levofloxacin 
Moxifloxacin 
Gatifloxacin
Second-line injectable agents Amikacin 
Capreomycin 
Kanamycin 
(Streptomycin)
Other core second-line agents Ethionamide/Prothionamide 
Cycloserine/Terizidone 
Linezolid 
Clofazimine
Add-on agents Bedaquiline 
Delamanid 
p-aminosalicylic acid 
Imipenem-cilastatina 
Meropenema 
Amoxicillin-clavulanatea 
(Thioacetazone)b
aCarbapenems and clavulanate are meant to be used together: 
clavulanate is available only in formulations combined with amoxicillin. 
bHIV status must be confirmed as negative before thioacetazone is 
started. Adapted from references 38 and 39.
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although this has improved in recent years, was still only 85% in 
20165. In 2014, 87% of HIV-positive TB cases globally received 
CPT29.
NTPs must be bold and aim for 100% HIV testing uptake and 
100% CPT and ART for those diagnosed HIV-positive. How this 
is best achieved is up to countries and depends on how well TB 
and HIV/AIDS services are decentralized along with the needed 
clinic infrastructure and trained health-care staff. Approaches 
need to be contextual and innovative, preferably aiming 
for a “one-stop-shop” service that integrates TB and HIV care57.
Diabetes mellitus
People with diabetes mellitus (DM) have a three-times-higher 
risk of TB compared with the general population58–60. Both 
type 1 and type 2 DM increase this risk, but as type 2 disease 
accounts for 90% or more of the global cases of DM, this type 
of DM dominates the interaction. In 2012, it was estimated 
that the number of adult TB cases associated with DM was just 
over 1 million, similar to what was observed at that time for 
HIV-associated TB60.
DM adversely affects TB treatment outcomes61. The reasons are 
not completely understood but include the immunosuppressive 
and biochemical effects of DM itself, drug–drug interactions, 
adverse events from medications, suboptimal adherence, and 
reduced bio-availability of the drugs. The risk of death during 
TB treatment is almost doubled among those with DM, and 
this risk increases to about five times when adjustments are 
made for age and other potential confounders61. Cardiovascular 
disease could explain an increased rate of deaths within months 
after starting anti-TB treatment62 and the much higher death 
rates among DM patients who smoke63. The risks of relapse TB 
in those who have completed anti-TB treatment are also higher 
among those with DM compared with those without61, and this 
further adds to the disease burden. DM is also an independent 
risk factor for the development of MDR-TB64.
Globally, the prevalence of DM among patients with TB 
ranges from 1.9% to 45%, and risk factors are older age, urban 
residence, sedentary life-style, and having a family history of 
DM65. The WHO and the International Union Against Tuber-
culosis and Lung Disease now recommend that all patients with 
TB be systematically screened for DM66, and implementation 
research within the general health services in India and China 
has shown the feasibility and effectiveness of screening for 
DM at the time of registering TB patients for treatment67,68. There 
is some evidence that improved management of DM and the use 
of metformin as the oral anti-diabetes medication reduce the 
risk of death during TB treatment, although these encouraging 
findings need confirmation69,70. With the global pandemic of DM 
escalating and seemingly out of control71, NTPs need to keep 
up to date with advances in the field of DM-associated TB and 
seriously consider setting up routine screening and care for DM.
Design and implement active case finding strategies 
for high-risk and vulnerable groups
In most TB endemic settings, TB case detection is based on 
passive case finding, namely waiting for symptomatic patients 
to seek health-care. This strategy, as shown consistently in 
TB prevalence surveys, is inadequate to detect the substantial 
burden of undiagnosed TB in the community72. Active case 
finding (ACF) is an additional approach, which proactively seeks 
to identify patients with TB.
Mathematical models suggest that ACF could increase TB case 
finding, and the WHO has provided guidelines for the system-
atic and active screening of high-risk groups (Table 6)73,74. In 
one review, the yields of newly diagnosed TB through ACF were 
0.7% in population-based community surveys, 2.2% in contact-
tracing studies, 2.3% in mines, 2.5% in prisons, 8.2% in medical 
and ART clinics, and 8.5% in HIV voluntary and counselling 
services75. Prisons and health-care facilities in low-resource 
settings are high-risk areas for intense TB transmission76,77, and 
ACF combined with other TB control measures would help to 
considerably reduce TB incidence in these settings. Interest 
has recently developed about screening people with DM for 
TB. There are no global data, but two large studies from China 
and India within the routine health services found that the 
yields of TB were significantly higher than those found from 
passive case finding amongst the general population78,79.
To reduce the “missing 4 million TB patients”, NTPs will have to 
take up ACF, but the scale and focus of what can be done must 
be contextualized and will be limited by available resources. 
People living with HIV (PLHIV) and household contacts 
are easily identifiable high-risk targets and they should be 
prioritized.
Amongst PLHIV, systematic TB screening (termed intensified 
case finding) is now an accepted part of the package of care. In 
2016, 88,200 (7%) of the 1.3 million PLHIV newly enrolled in 
HIV care were diagnosed with TB5, although this figure prob-
ably underestimates the true burden of TB in this population. 
Disseminated TB which is more prevalent in those with advanced 
immunodeficiency is difficult to diagnose in most health-care 
facilities in resource-poor settings, and autopsy studies show 
that much of it is diagnosed post-mortem and not recognized or 
identified during life80. For sick, immunocompromised patients, 
there is a promising bedside test involving measurement of urine 
lipoarabinomannan (LAM), one of the cell wall lipopolysaccha-
ride components of MTB. The urine test can be carried out with 
a Determine TB-LAM test strip (Alere, Waltham, MA, USA) 
with results in 30 minutes. Specificity is high and sensitivity 
increases as CD4 cell counts decrease to below 100 cells/µL81. 
Bedside urine LAM (with a positive result guiding the start of 
anti-TB treatment) on HIV-infected adults admitted to hospital 
in several African countries resulted in a decrease in mortality at 
2 months82. Xpert MTB/RIF can also be used on urine 
specimens to identify HIV-infected hospitalized patients with 
TB83. A new screening approach in Malawi and South Africa 
showed that testing people living with HIV and admitted to 
hospital with urine LAM and urine Xpert MTB/RIF in addition 
to sputum Xpert MTB/RIF resulted in increased overall TB diag-
nosis and treatment and reduced mortality in key subgroups84. 
Sick HIV-infected patients with pulmonary and disseminated TB 
often cannot cough up sputum, and the use of urine as a 
suitable and easy-to-collect specimen for investigation is a novel 
step forward.
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For years, NTPs have tried, with limited success, to screen house-
hold contacts of index smear-positive TB patients, focusing 
on children younger than 5 years of age. A recent systematic 
review showed that all household contacts (including adults) are 
at high risk of developing TB85. A cluster randomized trial in 
Vietnam, with repeated visits to households and assessments 
by symptoms, physical examination, and chest radiography, 
has shown the undoubted benefit and high yield of this ACF 
approach86. NTPs must seriously consider implementing and 
monitoring this ACF activity.
Treat latent tuberculosis infection in high-risk groups
ACF aims to identify amongst high-risk groups those with undi-
agnosed active TB and at the same time this approach can be 
used to identify and treat those with latent TB infection (LTBI) 
to prevent them from developing active disease. Thus, ACF 
is linked to the treatment of LTBI, and the two high-priority 
groups for the intervention are the same: PLHIV and house-
hold contacts of patients with TB. LTBI is diagnosed by the 
tuberculin skin test or interferon-gamma release assay87. Both 
tests are challenging to use in programmatic settings and this 
has often proven to be a bottleneck to treating LTBI88. Updated 
guidance from the WHO on the programmatic management 
of LTBI may help to move forward this important but generally 
neglected aspect of TB control (Table 7)89.
PLHIV deserve special mention. ART reverses the immune 
dysfunction associated with HIV and, as a result, has a potent 
TB-preventive effect90. At the program level, the increasing 
ART coverage in people living with HIV in Swaziland, 
Zimbabwe, and Malawi has been associated with a decrease 
in national TB case notification rates for both HIV-positive and 
HIV-negative persons91–93. Randomized controlled trials have 
shown that the effects of ART in reducing TB incidence may be 
augmented with the addition of isoniazid preventive therapy 
(IPT)94,95. There is further evidence to suggest that in high-TB 
exposure environments IPT might have to be given indefi-
nitely for sustained benefit: in this context, it is likely that 
IPT prevents new infection or reinfection from developing 
into active disease96. The number of PLHIV who received 
IPT in 2016 was 940,269; the largest proportion (41%) came 
from South Africa5. Despite progress in some other countries (for 
example, Malawi, Zimbabwe, and Mozambique), much remains 
to be done. NTPs need to liaise closely with National HIV/AIDS 
programs in this regard and decide whether and how best to 
scale up IPT alongside ART.
Engage with the private-for-profit sector
Many resource-poor countries have large and expanding 
private-for-profit health sectors, and many people with TB seek 
and receive care from private providers. This is especially so 
in Asia, but it is also a growing challenge in other parts of the 
world, including sub-Saharan Africa97,98. In recent years, the 
WHO has begun to address the issue of private-for-profit provid-
ers in TB prevention and care through an evolving global strategy 
called Public-Private Mix (PPM)98. Central to the concept of 
PPM and the delivery of quality TB care is the mix of “clinical 
tasks” (referrals of symptomatic patients, diagnosis, and 
prescribing treatment) and “public health tasks” (quality assurance, 
patient follow-up and support, recording, and reporting) and 
the linkage of private sector providers to local public sector 
TB programs. Since 2009, high-TB burden countries have 
reported on the contribution of PPM to TB case notifications, 
and in 2016 this was approximately 17% in India, 26% in 
Pakistan, 28% in Bangladesh, and 16% in Myanmar5. These 
reports, however, do not reflect ground realities where PPM is 
often limited to urban areas and a small proportion of targeted 
providers98. PPM must become an important partner of NTPs; 
the persisting challenges and potential ways of improving the 
service are outlined in Table 8. New guidance provided by the 
WHO in 2017 should help in this regard99.
Empower and strengthen the central unit of the 
National TB Programme
NTPs need a strong central unit to provide leadership, planning, 
training, drug and consumables forecasting, procurement, 
Table 6. World Health Organization recommendations on risk groups for screening.
Strong recommendationsa
Household and other close contacts should be systematically screened for active TB
People living with HIV should be screened for TB at each visit to a health facility
Current and past workers in workplaces with silica should be screened for active TB
Conditional recommendationsb
Systematic screening for active TB should be considered in prisons
Systematic screening for active TB should be considered in those with fibrotic chest radiograph lesions
Systematic screening for active TB should be considered for those seeking or in health-care
Systematic screening for active TB should be considered in other high-risk groups; these include 
people living in urban slums, homeless people, people living in remote areas, some indigenous 
populations, and migrants/refugees
TB, tuberculosis. aA strong recommendation is one in which the desirable effects clearly outweigh the undesirable 
effects and for which screening is judged to be feasible, acceptable, and affordable in all settings. bA conditional 
recommendation is one in which the desirable effects probably outweigh the undesirable effects. Adapted from 
reference 74.
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Table 8. Challenges and potential solutions for scaling up private-public mix.
Challenges 
Overburdened TB Programs
Fragmented private sector with limited capacity to undertake non-clinical tasks
Weak capacity of public sector to oversee and manage contracts with private organizations
Agreed regulations (e.g. mandatory TB case notifications) are not enforced
Insufficient financing
Potential solutions 
Get governments to commit to invest in the private sector
Consider the financing of private-public mix through universal health coverage
Set up permanent working linkages between TB programs and private health facilities
Use intermediary organizations to design, manage, and supervise contracts
Engage in business-friendly approaches using smart application of new digital technologies
Enforce regulations (mandatory TB case notifications through web-based systems: restrictions 
on private over-the-counter sales of anti-TB drugs)
TB, tuberculosis. Adapted from references 97 and 98.
Table 7. Guidance for diagnosing and treating latent tuberculosis infection.
At-risk populations for LTBI testing and 
treating
Adults, adolescents, children, and infants living with HIV 
 
HIV-negative household contacts of persons with bacteriologically confirmed TB 
(children, adolescents, and adults) 
 
Other HIV-negative at-risk groups, according to resources
Testing for LTBI Tuberculin skin test (TST) or interferon-gamma release assay (IGRA) wherever possible 
 
People living with HIV with a positive test benefit more from preventive treatment: where 
testing is possible, this can be used to identify such individuals 
 
TST or IGRA is not a requirement for initiating preventive treatment in people living with 
HIV or child household contacts younger than 5 years of age
Treatment options for LTBI Isoniazid monotherapy daily for 6 months 
 
Rifampicin and isoniazid daily for 3 months as alternative to isoniazid 
 
Rifapentine and isoniazid weekly for 3 months as alternative to isoniazid 
 
Isoniazid monotherapy daily for at least 36 months in people living with HIV in high-TB 
burden settings, regardless of whether they are receiving antiretroviral therapy
Preventive therapy for contacts of 
patients with multidrug-resistant TB
Treatment options based on individual risk assessment; strongly consider use of 
levofloxacin or moxifloxacin
LTBI, latent tuberculosis infection; TB, tuberculosis. Adapted from reference 89.
budgeting, supervision, monitoring and evaluation, and opera-
tional research. Ways to integrate TB program activities with 
other disease-related areas such as HIV/AIDS and DM need 
to be developed and implemented. NTPs also need to engage 
regularly with other stakeholders and government departments 
to make a strong case for reducing poverty and overcrowding 
and tackling the other key social determinants of TB.
Three areas need emphasis: supervision, research, and finances. 
Regular, supportive, and structured data-driven supervision 
coordinated by the central unit is essential to TB control. 
Supervision within communicable disease control programs 
helps to check whether guidelines are implemented, drug stocks 
are sound, records are accurate, and cohort analysis at peripheral 
levels is correct and meaningful7,100,101. In all of this, supervisors 
must recognize the potentially perverse nature of targets and 
ensure that NTPs do not drown in fake numbers102.
Operational research needs to be firmly embedded within the 
NTP, as this enables programs to carry out local research that 
contributes to knowledge, tools, interventions, and strategies 
that can enhance the quality and coverage of service delivery 
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and help inform better policy and practice103,104. The placement 
of operational research fellows within the central unit of NTPs 
greatly facilitates the implementation and value of this work105,106. 
NTPs must also form partnerships with academia to facilitate 
the conduct of meaningful clinical or cluster randomized trials, 
as demonstrated by the recent household contact assessment 
in Vietnam86.
In 2017, most of the funding for TB control efforts was 
provided by domestic sources (84% of the global total of USD 
$6.9 billion), although in low-income countries international 
donor funding, mainly through the Global Fund to fight AIDS, 
Tuberculosis and Malaria, exceeded domestic funding and this 
is likely to remain the case5. Development assistance for health 
is unlikely to increase in the future, so NTPs need to advocate 
strongly for domestic funding, ensure that spending is efficient 
and not wasteful of resources, and keep abreast of new innova-
tive international financing instruments which can benefit global 
health107. NTPs in low- and middle-income countries need to 
emphasize that the diagnosis and treatment of drug-sensitive and 
drug-resistant TB are very cost-effective when compared with 
the economic cost and productivity losses that may result from 
the disease108.
Conclusions
NTPs on their own cannot end the global TB epidemic, which 
will require accelerated socio-economic development, poverty 
alleviation, social protection, actions on other determinants of 
TB, strengthening of health systems, and expansion of universal 
health coverage. For this multi-sectoral response, there will need 
to be close engagement of communities, civil society organiza-
tions, the private sector, and different government ministries. 
New tools for preventing, diagnosing, and treating TB are also 
urgently needed6.
Nevertheless, NTPs play a crucial role. This article has high-
lighted the basic TB control principles that need to be adhered to, 
not just in planning but also in implementation. The glaring gaps 
in the delivery of diagnostic, treatment, and preventive services 
along with our remedial recommendations are summarized in 
Table 9. The quality of delivered care often falls short of inter-
national standards in both public and private sectors, and NTPs 
Table 9. Challenges and recommendations for National TB Programmes.
Category Challenges Proposed remedies
End TB Milestones/Targets on TB 
incidence and mortality
Presented globally as percentage reductions 
compared with 2015
Change percentage reductions into absolute 
“national” numbers against which to measure 
progress and present them for all levels of the 
health system
Optimize prompt and accurate 
diagnosis of TB
Inefficient use of smear microscopy and 
Xpert MTB/RIF
Develop algorithms for best use of smear 
microscopy/Xpert MTB/RIF; monitor numbers 
being screened, tests done, and results; monitor 
operational capacity of MTB/RIF instruments; 
keep abreast of new diagnostic molecular 
technology
Provide rapid, complete, and 
effective treatment to all those 
diagnosed with TB
Poor linkage of diagnosis and treatment; 
wrong denominator for measuring treatment 
outcomes; high rates of “not evaluated” 
Monitor and improve linkage to care; use 
diagnosed TB patients as the denominator for 
treatment outcomes; obtain treatment outcomes 
for transfer-out patients
Implement and monitor 
effective infection control 
practices for MTB 
Poor infection control practices and 
monitoring of TB infection control
Implement and monitor World Health 
Organization-recommended guidelines; monitor 
rates of TB in health workers
Diagnose and treat drug-resistant TB Poor linkage to care; continued use of 
inefficient CDST systems at national 
laboratories; long duration of therapy
Monitor and improve linkage to care; prioritize 
and plan for more efficient use of Xpert MTB/RIF; 
aim for short 9- to 12-month multidrug-resistant 
TB treatment; keep abreast of new diagnostic 
molecular technology
Diagnose and treat HIV infection and 
diabetes mellitus
HIV and diabetes increase TB mortality; 
suboptimal uptake of HIV testing, ART, and 
CPT; limited screening of TB patients for 
diabetes
Aim for 100% uptake of HIV interventions; scale 
up screening of TB patients for diabetes and 
provide optimal diabetes care during anti-TB 
treatment
ACF and treatment of LTBI Poor programmatic implementation of ACF 
and treatment of LTBI 
Design and implement strategies with particular 
focus on people living with HIV and household 
contacts
Engage with private-for-profit sector Poor implementation of the PPM strategy Focus on ways to improve the PPM strategy, 
especially in Asia
Empower and strengthen central 
units of TB Programs
Weak central units More focus on data-driven supportive 
supervision, operational research, and sustained 
financing
ACF, active case finding; ART, antiretroviral therapy; CDST, culture and drug susceptibility testing; CPT, cotrimoxazole preventive therapy; LTBI, latent 
tuberculosis infection; MTB, Mycobacterium tuberculosis; PPM, public-private mix; TB, tuberculosis.
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must step up to the plate, systematically measure and improve 
quality of care, and invest in quality improvement programs109.
New paradigms also have to be embraced or else the planned 
new trajectories for reducing TB incidence and mortality will 
never be achieved. As new tools are developed, there needs to 
be a fast-track system for getting them pilot-tested and scaled up 
in the field, and this will require a broad-minded approach from 
national TB leadership. The clock is ticking and we need to 
think and act differently!
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